IntraGel Therapeutics

Company Overview

Snapshot

Founded in December 2020 by Peter Siman, Avner Geva, and Avi Domb, IntraGel Therapeutics operates with 1–10 employees. The company has raised $7.45 million across 4 funding rounds from 4 investors. In August 2026, IntraGel Therapeutics signed strategic collaboration and investment agreements with UroGen Pharma.

Business overview

IntraGel Therapeutics is a research-driven company focused on developing advanced treatments for solid tumors through its gel-based drug delivery technology. The SRGel platform facilitates the local and prolonged release of various anti-cancer medications, aiming to maximize therapeutic effectiveness while minimizing systemic exposure and adverse effects. Built on natural and safe fatty acids, this injectable, biocompatible, and biodegradable gel is designed for easy placement in solid tumors, including those that are surgically inaccessible or resistant to chemo/radio therapies. The company's flagship product, TumoCure, combines SRGel with cisplatin for treating head and neck, and lung cancers, with ongoing development for other tumors and cancer types.

Strategic signal

In August 2026, IntraGel Therapeutics announced strategic collaboration and investment agreements with UroGen Pharma. This partnership signals significant validation for IntraGel's SRGel platform and its potential to advance investigational oncology therapies, particularly in sustained-release applications. For investors, this collaboration highlights a strong market entry and potential for accelerated development and commercialization of their drug delivery technology within the pharmaceutical sector.

Company Intelligence Q&A

What was the most recent strategic development for IntraGel Therapeutics?

In August 2026, IntraGel Therapeutics signed strategic collaboration and investment agreements with UroGen Pharma to advance sustained-release investigational oncology therapies.

Which company led the investment in IntraGel Therapeutics in August 2026?

In August 2026, UroGen Pharma led an undisclosed equity investment in IntraGel Therapeutics as part of a strategic collaboration.

When did IntraGel Therapeutics receive funding from NGT HealthCare II?

NGT HealthCare II provided follow-on funding to IntraGel Therapeutics in August 2023 and also participated in a Pre-Seed round in May 2023.

Which investor participated in IntraGel Therapeutics' Pre-Seed funding round in May 2023?

In May 2023, IntraGel Therapeutics received Pre-Seed funding from the Israel Innovation Authority and NGT HealthCare II.